NCT04229706 - A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

January 12, 2022

Study Completion Date

January 15, 2022

Conditions

Hyperplasia of Breast

Interventions

DRUG

High dose Xiang Ju Ru Pi Ning capsule

xingjurupining capsule,8 capsule,tid,3 months.

DRUG

Low dose Xiang Ju Ru Pi Ning capsule

xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.

DRUG

Xiang Ju Ru Pi Ning capsule placebo

xiangjurupining capsule,8 capsule,tid,3 months.

Trial Locations (8)

Baoding No.1 Hospital of TCM, Baoding

Dongfang Hospital ,Beijing University of Chinese Medicine, Beijing

Dongzhimen Hospital,Beijing University of Chinese Medicine, Beijing

Guangdong Provincial Hospital of TCM, Guangzhou

the First Affiliated Hospital of Guangzhou University of TCM, Guangzhou

Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai

SHUGUANG Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai

Weifang Traditional Chinese Hospital, Weifang

All Listed Sponsors

lead

Tasly Pharmaceutical Group Co., Ltd

INDUSTRY